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Abstract Background: The randomised phase 2 CABOSUN trial comparing cabozantinib
with sunitinib as initial therapy for advanced renal cell carcinoma (RCC) of intermediate or
poor risk met the primary end-point of improving progression-free survival (PFS) as assessed
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by investigator. We report PFS by independent radiology review committee (IRC) assessment,
ORR per IRC and updated overall survival (OS).
Patients and methods: Previously untreated patients with advancedRCCof intermediate or poor
risk by IMDC criteria were randomised 1:1 to cabozantinib 60 mg daily or sunitinib 50 mg daily
(4 weeks on/2 weeks off). Stratification was by risk group and presence of bone metastases.
Results: A total of 157 patients were randomised 1:1 to cabozantinib (n Z 79) or sunitinib
(nZ 78). Median PFS per IRC was 8.6 months (95% confidence interval [CI] 6.8e14.0) versus
5.3 months (95% CI 3.0e8.2) for cabozantinib versus sunitinib (hazard ratio [HR] 0.48 [95%
CI 0.31e0.74]; two-sided pZ 0.0008), and ORR per IRC was 20% (95% CI 12.0e30.8) versus
9% (95% CI 3.7e17.6), respectively. Subgroup analyses of PFS by stratification factors and
MET tumour expression were consistent with results for the overall population. With a median
follow-up of 34.5 months, median OS was 26.6 months (95% CI 14.6enot estimable) with cabo-
zantinib and 21.2 months (95% CI 16.3e27.4) with sunitinib (HR 0.80 [95% CI 0.53e1.21]. The
incidence of grade 3 or 4 adverse events was 68% for cabozantinib and 65% for sunitinib.
Conclusions: In this phase 2 trial, cabozantinib treatment significantly prolonged PFS per IRC
compared with sunitinib as initial systemic therapy for advanced RCC of poor or intermediate
risk.
Trial Registration Number: NCT01835158.
ª 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Despite many available treatment options, advanced
renal cell carcinoma (RCC) remains essentially incur-
able. International Metastatic Renal Cell Carcinoma
Database Consortium (IMDC) criteria were developed
in the era of targeted therapy to classify patients into
prognostic groups based on the number of established
risk factors (poor risk: 3e6, intermediate risk: 1e2, and
favourable risk: 0) [1]. Patients with intermediate or
poor risk disease (70e80% of all patients with advanced
RCC) have shorter survival duration compared with
favourable risk patients and have the greatest need for
more effective therapies.
VEGFR-targeted therapy is the current standard
first-line treatment for patients with advanced RCC
based on improvements in progression-free survival
(PFS) in phase 3 clinical trials, with sunitinib and
pazopanib as the most commonly used therapies [2].
Patients eventually develop disease progression, with
median PFS ranging from 8 to 11 months for sunitinib
and pazopanib in populations that include patients of all
risk groups [3e5]. Duration of PFS is shorter in inter-
mediate and poor risk patients; for example, in a mixed
population of intermediate or poor risk patients treated
with targeted therapy, median PFS can be less than 6
months, based on data from the IMDC [6].
The VEGF-signalling pathway is upregulated in clear
cell RCC due to inactivation of the VHL tumour sup-
pressor gene [7], providing a molecular rationale for the
use of VEGF-targeted therapies in this setting. Target-
ing oncogenic pathways involved in RCC in addition to
VEGF-signalling might result in therapeutic benefit.
Two relevant targets are MET and AXL, as both are
upregulated as a result of VHL loss and have been
associated with tumour progression, resistance to
VEGF-pathway inhibition in preclinical models, and
poor prognosis in patients with RCC [8e11].
Cabozantinib is an oral inhibitor of MET, AXL, and
VEGFR2 [12] that is approved for treatment of patients
with advanced RCC after prior antiangiogenic therapy
based on results from the phase 3METEOR trial [13,14].
The randomised, open-label phase 2 CABOSUN trial
(Alliance for Clinical Trials in Oncology study A031203)
compared cabozantinib versus sunitinib as initial targeted
therapy in patients with metastatic RCC of intermediate
or poor risk by IMDCcriteria. TheCABOSUNstudymet
the primary end-point of improving investigator-assessed
PFS with cabozantinib compared with sunitinib; median
PFS per investigator was 8.2 months with cabozantinib
versus 5.6 months with sunitinib (hazard ratio
[HR] Z 0.66, 95% confidence interval [CI] 0.46e0.95,
one-sided log-rank p Z 0.012) [15]. A retrospective
analysis of PFS and objective response rate (ORR) by a
central, blinded independent radiology review committee
(IRC) was performed to determine if independent
assessment supports the investigator results.
We report results of independent assessment of PFS
and ORR as well as updated overall survival (OS) for
the CABOSUN trial in patients with advanced RCC of
intermediate or poor risk. Subgroup analyses of PFS
based on stratification factors and tumour MET
expression level are also presented.
2. Methods
2.1. Study design and participants
CABOSUN (Alliance for Clinical Trials in Oncology
A031203) is a randomised, phase 2 trial conducted at 77
investigative centres in the United States. Eligible pa-
tients were 18 years of age or older with advanced or
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metastatic RCC with a clear-cell component and
measurable disease per investigator without previous
systemic treatment for RCC. Patients were required to
have had intermediate or poor risk disease per IMDC
criteria, an Eastern Cooperative Oncology Group
(ECOG) performance status (PS) of 0e2, and adequate
organ function and no uncontrolled significant illnesses.
Patients with treated, stable brain metastases were
allowed. Patients were required to have archival tumour
tissue but could choose not to consent to analysis of this
tissue for MET expression. The study was conducted in
accordance with Good Clinical Practice guidelines and
the Declaration of Helsinki, and the protocol was
approved by the institutional review board or ethics
committee at each centre. Each participant signed an
institutional review boardeapproved, protocol-specific
informed consent form in accordance with federal and
institutional guidelines. Safety was monitored by the
Alliance Data and Safety Monitoring Board (DSMB);
the majority of the voting DSMB members are not
affiliated with the Alliance, and voting quorums for a
DSMB meeting require that the majority of voting
members not belong to the Alliance.
2.2. Randomisation and blinding
Patients were randomised 1:1 to receive cabozantinib or
sunitinib. Randomisation was stratified by IMDC risk
group (intermediate or poor), and the presence of bone
metastases (yes or no) using the dynamic allocation
method. Randomisation occurred at the time of enrol-
ment using the web-based National Cancer Institute
Oncology Patient Enrollment Network (OPEN) system.
Patients and investigators were not blinded to treatment.
The central IRC was blinded to treatment assignment.
Aggregate efficacy analyses were not performed until
analysis of the primary end-point was triggered, with the
exception of a single planned futility analysis of PFS.
2.3. Procedures
Patients were randomly assigned to receive cabozantinib
60 mg once daily or to receive sunitinib 50 mg once daily
for 4 weeks, followed by a 2-week break. Cabozantinib
was provided by Exelixis, Inc. (South San Francisco,
CA, USA) and sunitinib was purchased commercially.
Dose could be modified by dose holds or reductions to
manage adverse events. Dose reductions were to 40 mg
and 20 mg for cabozantinib and to 37.5 and 25 mg for
sunitinib. Patients continued treatment until radio-
graphic disease progression as assessed by the investi-
gator, intolerance to therapy, or withdrawal of consent.
Crossover between treatment groups was not prescribed
by the protocol. One treatment cycle was defined as 6
weeks. Safety was assessed every cycle and included
adverse events, physical examination and standard lab-
oratory tests. Treatment-emergent adverse events were
reported and graded by the investigator according to the
National Cancer Institute Common Terminology
Criteria for Adverse Events (version 4.0). Some adverse
events (alanine aminotransferase increased, aspartate
aminotransferase increased, blood bilirubin increased,
electrocardiogram QT prolonged, fatigue, hypertension,
neutrophil count decreased, palmar-plantar eryth-
rodysesthesia syndrome, platelet count decreased,
diarrhoea and pancreatitis) were solicited at every visit.
For solicited adverse events, grade and relationship to
treatment were reported. For unsolicited adverse events,
grade 1 or 2 events were only required to be reported if
the investigator considered them to be treatment related.
Magnetic resonance imaging or computed tomogra-
phy scans were performed at baseline and every 12
weeks thereafter until progression or until 5 years after
randomisation. Radiographic images were collected
from the sites for retrospective assessment by a blinded
central independent review committee. Investigators and
the IRC assessed tumour response and progression
using Response Evaluation Criteria in Solid Tumors
(RECIST version 1.1) [16]. Partial and complete re-
sponses required confirmation 4 weeks after initial
response. Survival status was determined every 6 months
after discontinuation of study treatment.
Archival tumour tissue was analysed by immunohis-
tochemistry to determine MET expression level, based
on published procedures [14,17,18]. Formalin-fixed
paraffin-embedded tumour blocks were analysed by
the Department of Oncologic Pathology at Dana-
Farber Cancer Institute using the SP44 antibody (Ven-
tana Medical Systems, Inc, Tucson, AZ, USA) and
MET status was categorised as positive or negative
based on a cutoff of 50% of tumour cells stained
2 þ or 3 þ for positive status.
2.4. Outcomes
The primary end-point was PFS assessed by investi-
gator. Secondary end-points were ORR per investigator,
OS, and safety. PFS, ORR and best change in tumour
target lesions by independent review were post-hoc
retrospective analyses which were initiated after anal-
ysis of the primary end-point.
2.5. Statistical analyses
The study was designed to test the hypothesis that
cabozantinib increased the primary end-point of
investigator-assessed PFS compared with sunitinib. The
alternative hypothesis was that the hazard ratio for PFS
was 0.67 favouring the experimental arm (cabozantinib)
over the control arm (sunitinib). With 123 PFS events,
the log-rank test had 85% power to detect a HR of 0.67
with a one-sided type I error of 0.12 (equivalent under
assumptions of exponential event-time distributions and
proportional hazard to an increase in median PFS from
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8 months in the sunitinib arm to 12 months in the
cabozantinib arm). The planned sample size was 150
patients based on additional assumptions of an accrual
rate of 5.8 patients per month for 24 months, 20 months
of follow-up after closure to randomisation, and a 7%
ineligibility rate. A single futility analysis was conducted
when the investigator-determined events reached 50% of
the required total.
PFS was defined as the time from randomisation to
the earlier of radiographic progression per RECIST
version 1.1 or death due to any cause [15]. For retro-
spective analyses of PFS per IRC, censoring rules per
the Food and Drug Administration (FDA) Guidance on
Oncology Endpoints [19] were employed. For patients
who had not experienced an event at the time of data
cutoff, had two or more missing adequate tumour as-
sessments immediately before radiographic progression
or death, or had received systemic subsequent anticancer
therapy, event-time was censored at the time of their
most recent adequate tumour assessment before the date
these criteria were met. The application of these FDA-
recommended censoring rules for PFS, which were not
applied in the previous report of investigator-assessed
PFS [15], necessarily reduces the number of events
available for analysis. To increase the number of events
included in the current analysis, the data cutoff for
radiographic end-points was extended from April 11,
2016 (the date of the 123rd investigator-determined event
in the previous report) to September 15, 2016. A sup-
portive analysis of investigator-assessed PFS was also
conducted with FDA censoring rules using the
September 15, 2016 cutoff date.
OS was defined as the time from randomisation to
death due to any cause and was analysed with a data
cutoff of July 01, 2017. For patients who were alive at
the time of data cutoff or were permanently lost to
follow-up, duration of OS was right censored at the
earliest of date of withdrawal of consent from all follow-
up, data cutoff date, or the date the patient was last
known to be alive.
Analyses of efficacy end-points were performed in all
randomised patients based on the intent-to-treat princi-
ple. Safety was assessed in patients who received at least
one dose of study treatment. Analyses of PFS used a
stratified log-rank statistic to compare the two treatment
arms; stratification factors were those used for the ran-
domisation (IMDC risk group [intermediate or poor]
and bone metastases [yes or no]). The KaplaneMeier
method [20] was used to estimate the median PFS and
median OS and associated 95% confidence intervals.
Hazard ratios were estimated using a Cox proportional-
hazard regression model and adjusted with the stratifi-
cation factors [21]. For subgroup analyses of PFS, all
hazard ratios are unstratified. ORR was the proportion
of patients with confirmed complete or partial responses
per RECIST. Point estimates of ORR with 95% confi-
dence intervals were calculated using exact methods.
Although the original statistical design used one-sided p-
values, all p-values presented herein are two-sided for
consistency with previously published results for cabo-
zantinib in RCC. HRs and CIs for the secondary end-
points are to be considered descriptive, and p-values are
not reported because the study did not have prespecified
hypotheses for secondary end-points, and no adjust-
ments were made for multiple testing. SAS software
(version 9.1 or higher) was used for all analyses.
2.6. Role of the funding source
The study was designed by the Alliance for Clinical
Trials in Oncology, endorsed by the ECOGeAmerican
College of Radiology Imaging Network Group and
approved by the Cancer Therapy Evaluation Program
of the National Cancer Institute part of the National
Institutes of Health (the funder). The Alliance Statistics
and Data Center performed patient registration, data
collection, and all previously published statistical ana-
lyses and interpretations [15]. Exelixis initiated the
analysis of PFS and tumour response by the central IRC
and arranged for collection of radiographic images for
IRC assessments. All other data presented herein were
collected by the Alliance, and quality of those data was
ensured by review by the Alliance Statistics and Data
Center and by the study chairperson following Alliance
policies. Statistical analyses presented herein were con-
ducted by Exelixis in collaboration with the Alliance.
The authors had access to the raw data. The first draft
was written by the corresponding author in collabora-
tion with Exelixis. Medical writing support as well as
cabozantinib supply for the study were provided by
Exelixis. All authors gave final approval to submit the
manuscript, and the corresponding author had final re-
sponsibility for the decision to submit for publication.
3. Results
From July 9, 2013 to April 6, 2015, 157 patients were
randomised 1:1 to receive cabozantinib (n Z 79) or
sunitinib (n Z 78). Overall, baseline demographics and
characteristics were balanced between treatment groups
(Table 1). Eighty-one percent of patients were interme-
diate risk and 19% were poor risk according to IMDC
criteria. Twenty-five percent of patients had not had
prior nephrectomy, 36% had bone metastases and 73%
had two or more metastatic sites. Tumour MET status
was determined for 83% of patients; 39% of all rando-
mised patients were MET positive and 44% were MET
negative.
As of the September 15, 2016 data cutoff date for
PFS per IRC, 10 (13%) patients in the cabozantinib
group and 2 (3%) patients in the sunitinib group
remained on study treatment (Fig. 1). Median duration
of follow-up through this date was 25.0 months (IQR
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21.9e30.9). For the IRC assessment, radiographic
tumour images were available for 156 of 157 patients
(one site with one patient in the sunitinib group declined
to participate in radiographic image collection). For
these 156 patients, 100% of the known tumour images
through the data cutoff were retrieved.
As of the September 15, 2016 cutoff date, 92 PFS
events were observed (43 with cabozantinib and 49 with
sunitinib) as assessed by the IRC. Cabozantinib signifi-
cantly improved PFS per IRC (Fig. 2); median PFS per
IRC was 8.6 months (95% CI 6.8e14.0) with cabo-
zantinib versus 5.3 months (95% CI 3.0e8.2) with
sunitinib (HR 0.48 [95% CI 0.31e0.74]; p Z 0.0008).
Results per investigator assessment using the same
cutoff date and censoring rules were consistent with
those from the independent assessment; median PFS per
investigator was 8.3 months (95% CI 6.5e12.4) with
cabozantinib versus 5.4 months with sunitinib (95% CI
3.4e8.2; HR 0.56 [95% CI 0.37e0.83]; p Z 0.0042).
Subgroup analyses of PFS per IRC assessment based
on the stratification factors andMET expression level are
presented in the appendix (Appendix p 4). The relative
treatment effect in subgroups based on stratification
factors was consistent with the result for the overall
population. ForMET-positive patients (nZ 62), median
PFS was 13.8 months (95% CI 5.7e22.1) with cabo-
zantinib and 3.0 months (95% CI 2.5e5.4) with sunitinib
(HR 0.32 [95% CI 0.16e0.63]). For MET-negative pa-
tients (n Z 69), median PFS was 6.9 months (95% CI
5.4e14.6) with cabozantinib and 6.1 months (95% CI
3.6e9.6) with sunitinib (HR 0.67 [95% CI 0.37e1.23]).
As of September 15, 2016, any reduction in tumour
target lesions by IRC assessment was observed in 63
(80%) of 79 patients with cabozantinib compared with
39 (50%) of 78 patients with sunitinib (Fig. 3).
Confirmed objective responses per IRC were observed in
16 patients (20% [95% CI 12.0e30.8]) in the cabozanti-
nib group and 7 patients (9% [95% CI 3.7e17.6]) in the
sunitinib group (Table 2). All responses were partial
responses. The disease control rate (complete
responses þ partial responses þ stable disease) was 75%
(59 of 79 patients) with cabozantinib and 47% (37 of 78
patients) with sunitinib. Using the same cutoff date,
confirmed objective responses per investigator assess-
ment were observed in 26 patients (33% [95% CI
22.7e44.4]) in the cabozantinib group and 9 patients
(12% [95% CI 5.4e20.8]) in the sunitinib group
(Appendix p 5). One confirmed complete response per
investigator was observed with cabozantinib; all other
responses were partial responses. The disease control
rate per investigator was 76% (60 patients) with cabo-
zantinib and 49% (38 patients) with sunitinib.
For ORR per IRC, images for six patients in the
cabozantinib group and 18 patients in the sunitinib
group were unevaluable or missing for tumour response.
These patients discontinued or did not receive study
treatment for the following reasons: adverse event (5 in
the cabozantinib group versus 6 in the sunitinib group),
withdrew consent (1 versus 9), death (0 versus 2) and
disease progression (0 versus 1). Baseline characteristics
and disposition for the patients who had unevaluable or
missing post-baseline radiographic images compared
with those whose images were adequately assessed are
summarised in the appendix (Appendix p 6). Some
characteristics differed; for example, in the sunitinib
group, among those who had unevaluable or missing
post-baseline radiographic images, 28% of patients had
poor risk disease, and 22% of patients had an ECOG PS
of 2 compared with 17% with poor risk disease and 10%








Age (years) 63 (56e69) 64 (57e71)
Sex
Male 66 (84%) 57 (73%)
Female 13 (16%) 21 (27%)
Ethnic origin
White 70 (89%) 75 (96%)
Black or African American 3 (4%) 2 (3%)
Other 7 (9%) 1 (1%)
ECOG performance status
0 36 (46%) 36 (46%)
1 33 (42%) 32 (41%)
2 10 (13%) 10 (13%)
IMDC risk group
Intermediate 64 (81%) 63 (81%)
Poor 15 (19%) 15 (19%)
Bone metastasis per IxRS
Yes 29 (37%) 28 (36%)
No 50 (63%) 50 (64%)
Prior nephrectomy
Yes 57 (72%) 60 (77%)
No 22 (28%) 18 (23%)
MET statusa
Positive 32 (41%) 30 (38%)
Negative 39 (49%) 30 (38%)
Missing 8 (10%) 18 (23%)
Sum of diameters of
lesions per RECIST
per investigator (cm)
7.2 (4.3e11.7) 8.1 (4.7e13.4)
Number of metastatic
sites per investigator
1 17 (22%) 26 (33%)
2 37 (47%) 20 (26%)
3 25 (32%) 32 (41%)
Metastatic sites per investigator
Nodal 45 (57%) 42 (54%)
Lung 55 (70%) 54 (69%)
Liver 15 (19%) 20 (26%)
Bone 31 (39%) 30 (38%)
CNS/brain 3 (4%) 2 (3%)
Data are n (%) or median (IQR).
Abbreviations: IMDC, International Metastatic Renal Cell Carcinoma
Database Consortium criteria; IxRS, interactive web/voice response
system.
a Based on tumour MET levels by immunohistochemistry.
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As of the July 01, 2017, data cutoff date for OS with a
median follow-up of 35.4 months (IQR 31.4e40.4), 90
deaths had occurred (43 of 79 patients in the cabo-
zantinib group and 47 of 78 patients in the sunitinib
group). Median OS was 26.6 months (95% CI 14.6enot
estimable) with cabozantinib and 21.2 months (95% CI
16.3e27.4) with sunitinib. The stratified HR for death
was 0.80 (95% CI 0.53e1.21; Fig. 4). Subsequent anti-
cancer therapy (surgery, radiotherapy, or systemic
therapy) was received by 51 (65%) patients in the
cabozantinib group and 50 (64%) patients in the
sunitinib group with systemic therapy received by 48
(61%) and 48 (62%), respectively (Appendix p 7). Sys-
temic therapies included tyrosine kinase inhibitors (38
[48%] in the cabozantinib group versus 37 [47%] in the
sunitinib group), mTOR inhibitors (15 [19%] versus 18
[23%]) and PD-1 checkpoint inhibitors (14 [18%] versus
15 [19%]).
As of the September 15, 2016 data cutoff date, me-
dian duration of exposure was 6.5 months (IQR
2.8e16.5) for cabozantinib-treated patients (n Z 78)
and 3.1 months (IQR 2.0e8.2) for sunitinib-treated
patients (n Z 72). Dose reductions occurred for 36
cabozantinib-treated patients (46%) and 25 sunitinib-
treated patients (35%). The median average daily dose
was 50.3 mg (IQR 41.8e60.0) for cabozantinib and
44.7 mg (IQR 35.1e50.0) for sunitinib (while on study
treatment). Treatment discontinuation due to an adverse
event occurred for 16 patients (21%) with cabozantinib
and 16 patients (22%) with sunitinib.
Adverse events of any grade regardless of causality
were recorded for 75 (96%) cabozantinib-treated pa-
tients and 71 (99%) sunitinib-treated patients (Table 3).
Grade 3 or 4 adverse events occurred for 53 (68%)
cabozantinib-treated patients and 47 (65%) sunitinib-
treated patients. The most common grade 3 or 4
adverse events were hypertension (22 [28%] in the
cabozantinib group versus 15 [21%] in the sunitinib
group), diarrhoea (8 [10%] versus 8 [11%]), fatigue (5
[6%] versus 12 [17%]) and platelet count decreased (1
[1%] versus 8 [11%]). Grade 5 adverse events occurred
157 patients randomly assigned
79 Allocated to cabozantinib
78 Received cabozantinib
78 Allocated to sunitinib
72 Received sunitinib
1 did not receive study drug
1 withdrew consent
6 did not receive study drug
6 withdrew consent
68 Discontinued cabozantinib
44 Disease progression 











79 analysed for PFS, objective
      response rate, and overall survival
78 analysed for safety
78 analysed for PFS, objective
      response rate, and overall survival
72 analysed for safety
10 continued cabozantinib
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Fig. 2. KaplaneMeier plot of progression-free survival per inde-
pendent radiology review committee through September 15,
2016. All 157 randomised patients were included in the analysis.
HR, hazard ratio; PFS, progression-free survival.
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for 3 (4%) patients with cabozantinib and 7 (10%) pa-
tients with sunitinib. Two grade 5 adverse events (renal
failure acute and sepsis) were considered related to
cabozantinib and four grade 5 adverse events (angiop-
athy, sepsis, respiratory failure, sudden death) were
considered related to sunitinib.
4. Discussion
Cabozantinib significantly prolonged PFS per IRC
assessment compared with sunitinib as initial targeted
therapy in patients with advanced RCC of intermediate
or poor risk by IMDC criteria. Median PFS per IRC
was 8.6 months with cabozantinib versus 5.3 months
with sunitinib (HR 0.48). Subgroup analyses of PFS
based on stratification factors showed a relative treat-
ment effect consistent with the overall population re-
sults. The ORR per IRC was about two times higher
with cabozantinib than with suntinib. OS analysis
showed a HR <1, observationally favouring cabo-
zantinib, although the 95% CI included 1.
The randomised, phase 2 CABOSUN trial was
designed to evaluate whether cabozantinib increased
PFS compared with sunitinib. Consistent with the phase
2 design, the primary end-point was investigator-
assessed PFS with a one-sided p-value and high critical
value of 0.12. The retrospective blinded independent
assessment by a central IRC was initiated after the study
met the primary end-point and used censoring rules per
FDA guidance for the analysis. The application of FDA
censoring resulted in fewer events in the IRC analysis
compared with the previous investigator analysis despite
additional follow-up of approximately 5 months.
Missing or inadequate tumour assessments immediately
preceding an event or receipt of subsequent systemic
therapy caused censoring in the current analysis but not
in the previous analysis. The results by IRC assessment
were highly statistically significant (two-sided p-
value Z 0.0008) and consistent with the previous
investigator assessment [15] as well as the investigator
assessment reported here, which was conducted with the
same data cutoff and FDA censoring rules.
The ORR was improved with cabozantinib compared
with sunitinib for both the IRC and investigator as-
sessments. Although the ORR with cabozantinib was
higher when assessed by the investigator, the disease
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Fig. 4. KaplaneMeier plot of overall survival through July 01, 2017.
All 157 randomised patients were included in the analysis. HR,



































Fig. 3. Best target lesion change from baseline. *Confirmed partial responses. Six patients in the cabozantinib group and 18 patients in the
sunitinib group were unevaluable because they had no adequate post-baseline imaging assessments (Table 2).
Table 2





Objective response rate (95% CI) 20% (12%e31%) 9% (4%e18%)
Best overall response
Confirmed partial response 16 (20%) 7 (9%)
Stable disease 43 (54%) 30 (38%)
Progressive disease 14 (18%) 23 (29%)
Unevaluable or missinga 6 (8%) 18 (23%)
Data are % or n (%) and are as of September 15, 2016. All responses
were partial responses.
a Unevaluable or missing for the following reasons: cabozantinib:
adverse event (5), withdrew consent (1); sunitinib: adverse event (6),
death (2), disease progression (1), withdrew consent (9).
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assessments, indicating a shift from confirmed partial
response to stable disease in the IRC assessment. In
addition, the majority of patients in the cabozantinib
group had regression in tumour target lesions by IRC,
and the percentage who experienced tumour reduction
was about 1.5 times higher than that observed with
sunitinib, similar to the original investigator review [15].
More patients did not have adequate tumour assess-
ments in the sunitinib group (nZ 18) compared with the
cabozantinib group (n Z 6) primarily because of early
withdrawn consent, death or disease progression. To
evaluate whether this difference might have affected the
radiographic efficacy end-points, baseline characteristics
of the 18 patients in the sunitinib group whose radio-
graphic images were missing or unevaluable for tumour
response were compared with those of the remaining 60
sunitinib group patients with adequate assessments. A
higher percentage of patients with missing or unevaluable
assessments were classified as poor risk, ECOG PS 2 and/
or had other factors associated with poor prognosis than
the patients who were adequately assessed. Therefore, the
missing tumour assessment data for these patients are
unlikely to have unfavourably affected the radiographic
efficacy outcomes in the sunitinib group.
The median PFS per IRC of sunitinib in this study
(5.3 months) and ORR per IRC (9%) were lower than
that those previously reported for sunitinib in patients
with advanced RCC [15]. In the COMPARZ trial, me-
dian PFS per IRC with sunitinib was 9.5 months and
ORR per IRC was 25% [3]; however, as discussed in
Choueiri et al. [15], the present study included only
patients with intermediate or poor risk disease, whereas
the COMPARZ trial included patients of all risk groups
(favourable, intermediate or poor). Patients with inter-
mediate or poor risk disease treated with targeted ther-
apy have shorter duration of PFS [6]. Median PFS per
IRC for suntinib in the CABOSUN study was also
shorter than the value of 8.4 months for suntinib re-
ported for patients with intermediate or poor risk RCC
in the CheckMate-214 study [22,23].
Cross study comparisons are confounded by uncon-
trolled variables in patient characteristics and physician
practice. The CABOSUN study included a relatively
high incidence of patients with poor prognostic features
not explicitly included in the IMDC criteria, including
the presence of bone metastases [24], lack of prior ne-
phrectomy [25], greater number of metastatic sites, and
worse ECOG PS [26,27]. Furthermore, PFS may be
shorter in the cooperative group setting, which is more
similar to real-world experience compared with
industry-sponsored trials. For example, in the CALGB
90206 trial of interferon-alpha with or without
Table 3
All-causality adverse events.
Adverse event Cabozantinib (N Z 78) Sunitinib (N Z 72)
Grade 1e2 Grade 3 Grade 4 Grade 1e2 Grade 3 Grade 4
Any adverse event 19 (24%) 45 (58%) 8 (10%) 17 (24%) 42 (58%) 5 (7%)
Diarrhoeaa 49 (63%) 8 (10%) 0 31 (43%) 8 (11%) 0
AST increaseda 45 (58%) 1 (1%) 1 (1%) 20 (28%) 2 (3%) 0
Fatiguea 45 (58%) 5 (6%) 0 37 (51%) 12 (17%) 0
ALT increaseda 39 (50%) 3 (4%) 1 (1%) 20 (28%) 0 0
Decreased appetite 33 (42%) 4 (5%) 0 22 (31%) 1 (1%) 0
Dysgeusia 32 (41%) 0 0 21 (29%) 0 0
Hypertensiona 30 (39%) 22 (28%) 0 17 (24%) 14 (19%) 1 (1%)
Platelet count decreaseda 29 (38%) 1 (1%) 0 36 (50%) 6 (8%) 2 (3%)
PPESa 27 (35%) 6 (8%) 0 21 (29%) 3 (4%) 0
Anaemia 25 (32%) 1 (1%) 0 31 (43%) 2 (3%) 0
Stomatitis 25 (32%) 4 (5%) 0 17 (24%) 4 (6%) 0
Nausea 23 (29%) 2 (3%) 0 25 (35%) 3 (4%) 0
Weight decreased 22 (28%) 3 (4%) 0 12 (17%) 0 0
Dyspepsia 21 (27%) 0 0 12 (17%) 0 0
Hypothyroidism 18 (23%) 0 0 4 (6%) 0 0
Blood creatinine increased 17 (22%) 2 (3%) 0 13 (18%) 2 (3%) 0
Vomiting 17 (22%) 1 (1%) 0 14 (19%) 2 (3%) 0
Dizziness 16 (21%) 1 (1%) 0 16 (22%) 0 0
Dysphonia 16 (21%) 1 (1%) 0 1 (1%) 1 (1%) 0
Hyperglycaemia 16 (21%) 0 0 7 (10% 4 (6%) 0
Neutrophil count decreaseda 12 (15%) 0 0 22 (31%) 3 (4%) 0
White blood cell count decreased 9 (12%) 0 0 23 (32%) 2 (3%) 0
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; PPES, palmar-plantar erythrodysesthesia syndrome.
Treatment-emergent adverse events are summarised as of September 15, 2016. Adverse events that were reported as grade 1 or 2 in at least 20% of
the patients in either study group are shown, irrespective of whether the event was considered by the investigator to be related to the study
treatment. Some adverse events were solicited at every visit. For unsolicited adverse events, grade 1 or 2 events were only required to be reported if
they were considered related by the investigator. Patients are counted once at the highest grade for each preferred term. The severity of adverse
events was graded by the investigator according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).
a Solicited adverse event.
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bevacizumab in untreated patients with advanced RCC,
median PFS was 1.7 months shorter in the combination
arm on the CALGB study [28] compared with the value
reported for this combination in the phase 3 industry-
sponsored Avoren study [29].
Updated OS included an additional 9.5 months of
follow-up compared with the previous analysis and
showed a hazard ratio <1, observationally favouring
cabozantinib over sunitinib, consistent with the previous
results [15]. This phase 2 study was designed to evaluate
the primary end-point of PFS, and the secondary end-
point of OS was not powered for determination of sur-
vival differences. Importantly, improved PFS has been
shown to correlate with prolonged survival in RCC by
several retrospective studies, and PFS has been used as
the primary end-point for many pivotal clinical studies
in RCC [30,31].
Updated safety was consistent with that reported at
the earlier cutoff and with the known safety profiles of
both study treatments [4,14,15]. The most common
adverse events were diarrhoea, hypertension, fatigue,
and AST increased with cabozantinib and fatigue,
platelet count decreased and diarrhoea with sunitinib. In
this study, some adverse events were solicited, which
may have increased the reported incidence of these
events. Conversely, adverse events that were unsolicited
and grade 1 or 2 did not have to be reported unless
considered treatment related by the investigator, which
would likely decrease the recorded incidence of these
events. Dose reductions to manage adverse events were
frequent in both treatment groups, and the incidence of
treatment discontinuation due to adverse events was
similar with both study treatments.
The combination of nivolumab and ipilimumab was
recently shown to significantly improve OS compared
with sunitinib in patients of intermediate or poor IMDC
risk in a phase 3 study of previously untreated patients
with advanced RCC [23]. PFS was also improved in
these patients, although the result was not statistically
significant [22,23]. The improvement in PFS was only
observed in the subgroup of intermediate or poor risk
patients with high tumour PD-L1 expression (HR 0.46
for PD-L1 expression  1% versus HR 1.00 for PD-L1
<1%). Furthermore, PFS was shorter for the combina-
tion regimen compared with sunitinib in patients of
favourable IMDC risk (HR 2.17; p < 0.0001), who have
lower tumour PD-L1 expression levels. These results
suggest that patient characteristics may be important in
the selection of first-line treatment and that regimens
that combine checkpoint inhibitors with cabozantinib
should be explored as first-line therapy.
The observed improvement in PFS with cabozantinib
compared with sunitinib may be due, in part, to inhi-
bition of MET and AXL by cabozantinib in addition to
VEGF receptors. Subgroup analyses of PFS based on
MET expression level favoured cabozantinib over
sunitinib (HR < 1) regardless of MET status. Although
the HR more strongly favoured cabozantinib for MET-
positive versus MET-negative patients, subgroup sizes
were small and analyses were descriptive.
Cabozantinib treatment resulted in clinically mean-
ingful and statistically significant prolongation of PFS
per IRC compared with sunitinib as initial targeted
therapy in patients with advanced RCC in this phase 2
trial. The independent assessment confirms the
investigator-assessed results for PFS and supports that
cabozantinib is a potential treatment option as initial
therapy for patients with advanced RCC of intermediate
or poor risk.
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